HERO STUDY CONFIRMS EXCELLENT CLINICAL OUTCOMES FOR **SINUS-SUPERFLEX-635** STENT

The multicenter, prospective **HERO** Registry evaluated the safety and performance of the **sinus-SuperFlex-635** self-expanding nitinol stent (optimed Medizinische Instrumente GmbH) in the treatment of atherosclerotic lesions of the superficial femoral artery (SFA) and proximal popliteal artery (P1).
A total of 117 patients were enrolled across 7 centers in Belgium, with follow-ups at 1 and 12 months.

Study Highlights

Results at 12 months demonstrate high primary patency (78.5 %), low TLR (8.4 %), and an exceptionally low stent fracture rate (0.9 %), confirming both safety and durability even in complex lesions.
The stent's unique hybrid design — closed-cell ends for secure fixation and open-cell flexibility in the mid-section — ensures reliable performance and excellent vessel adaptability. Patients achieved marked clinical improvement, with > 88 % reaching Rutherford 0–1 at follow-up.

This registry promotes the sinus-Superflex-635 stent as a safe and reliable option for endovascular treatment of complex femoropopliteal lesions due to the high visibility and easy deployment.



KEY TAKEAWAYS

78.5 % primary patency & 91.6 % freedom from TLR at 12 months	Comparable or superior to major nitinol stent trials (RESILIENT, MISAGO, EPIC, SMART).
Exceptionally low stent fracture rate (0.9 %)	Demonstrates mechanical reliability and long-term safety.
Strong clinical improvement (Rutherford class 0–1 in > 88 % of patients)	Demonstrates clear clinical benefit for patients.
Optimized design for long lesions and challenging anatomy	Reduces need for stent overlap and risk of restenosis.